Britain and America have agreed to a important commercial pact that will keep zero import taxes on UK pharmaceutical products being sold in the American market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has agreed to boost expenditure on drugs through the National Health Service (NHS). This pledge ensures that import taxes on these key goods will stay at zero for a period of three years.
This agreement follows earlier statements to dramatically increase duties on branded drug products, with figures floated up to one hundred percent.
"This agreement between the United Kingdom reinforces the worldwide climate for new treatments and establishes much-needed balance to transatlantic drug exports," a statement declared.
Commercial Impact
Drugs constitute one of the the United Kingdom's most significant export categories to the US, which is by far the largest buyer for leading companies like GSK and AstraZeneca.
Statistics reveal that in the one-year period prior to September, the UK shipped medicines worth £11.1bn to the US. This figure represented nearly one-fifth of total UK exports in that timeframe.
"This deal safeguards employment, boosts investment and paves the way for the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary stated.
Detailed UK Commitments
The deal involves several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will increase the price threshold at which it judges new treatments to be too expensive by 25%.
- Boosted Medicine Funding: There is a aim to raise total NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The sum manufacturers must refund to the NHS to prevent overspending will be limited at fifteen percent. Last year, rebates topped twenty percent.
Recent Tensions
The pact comes amid a protracted tension between the pharmaceutical industry and the British authorities over spending levels and NHS adoption.
The disagreement were intensified by assertions that US patients were charged a premium for the equivalent treatments than people in the UK and Europe.
In recent months, several large pharmaceutical investments in the UK have been halted or abandoned, while major expansions have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS needed to increase expenditure on medicines, noting that its budget allocation on drugs had shrunk as a share of its overall budget over the last ten years.
